Themajority of mutations in the AR are identified in the metastases, rather than in theprimary tumors (Marcelli et al.2000) and may enable the AR to bind some antiandrogens, such as flutamide andbicalutamide, that act as AR agonists and fuel tumor cell growth (Buchanan et al. 2001, Bohl et al. 2005a,b). The gene discussed is AR; the disease is neoplasm.